Related references
Note: Only part of the references are listed.Rationale and design of the dal-OUTCOMES trial: Efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome
Gregory G. Schwartz et al.
AMERICAN HEART JOURNAL (2009)
Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone
M. J. Forrest et al.
BRITISH JOURNAL OF PHARMACOLOGY (2008)
Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk
Alexander Thompson et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2008)
Effects of torcetrapib in patients at high risk for coronary events
Philip J. Barter et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
High-density lipoprotein as a therapeutic target - A systematic review
Inder M. Singh et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2007)
Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial
Michiel L. Bots et al.
LANCET (2007)
Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia
John J. P. Kastelein et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Effect of torcetrapib on the progression of coronary atherosclerosis
Steven E. Nissen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Relation between on-treatment increments in serum high-density lipoprotein cholesterol levels and cardiac mortality in patients with coronary heart disease (from the bezafibrate infarction prevention trial)
I Goldenberg et al.
AMERICAN JOURNAL OF CARDIOLOGY (2006)
Benefits of niacin in patients with versus without the metabolic syndrome and healed myocardial infarction (from the Coronary Drug Project)
PL Canner et al.
AMERICAN JOURNAL OF CARDIOLOGY (2006)
Effectiveness of inhibition of cholesteryl ester transfer protein by JTT-705 in combination with Pravastatin in type II dyslipidemia
JA Kuivenhoven et al.
AMERICAN JOURNAL OF CARDIOLOGY (2005)
The relationship between cholesteryl ester transfer protein levels and risk factor profile in patients with familial hypercholesterolemia
GJ de Grooth et al.
ATHEROSCLEROSIS (2004)
Plasma levels of cholesteryl ester transfer protein and the risk of future coronary artery disease in apparently healthy men and women - The prospective EPIC (European Prospective Investigation into Cancer and Nutrition) - Norfolk population study
SM Boekholdt et al.
CIRCULATION (2004)
Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans - A randomized phase II dose-response study
GJ de Grooth et al.
CIRCULATION (2002)
Relation of gemfibrozil treatment and lipid levels with major coronary events - VA-HIT: A randomized controlled trial
SJ Robins et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2001)
Association of cholesteryl ester transfer protein-TaqIB polymorphism with variations in lipoprotein subclasses and coronary heart disease risk -: The Framingham study
JM Ordovas et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2000)
Share Paper
